For almost 90 years following the original description of Alois Alzheimer's patient and the identification of Alzheimer's disease (AD) (Alzheimer, 1907), physicians faced the bleak prospect of observing the inexorable and relentless decline in cognition, function, and behavior with little or no opportunity for therapeutic intervention. In the last 5 years clinicians have finally been provided with a class of medications, the cholinesterase (ChE) inhibitors, which have passed the test of efficacy and safety in the symptomatic management of AD and related dementias. With the arrival of donepezil, rivastigmine, and galantamine as the second generation of ChE inhibitors, a renewed and sustained interest in the diagnosis and care of AD patients might have been anticipated. However, there remains residual therapeutic nihilism and skepticism over the utility of these treatments in some quarters of the medical community and among some paying authorities. In moving forward and addressing these concerns, we must reflect carefully on the question, “What have we learned about the ChE inhibitors so far?”
